

CITATION REPORT

List of articles citing

A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.

DOI: 10.1007/s11096-022-01400-z

International Journal of Clinical Pharmacy, 2022, , 1.

Source: <https://exaly.com/paper-pdf/134991943/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study. <i>Psoriasis: Targets and Therapy</i> , Volume 12, 205-212	2.4	2
2	Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Volume 15, 1649-1658		3
1	Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China.		0